Borate-Modified Recombinant Type XVII Collagen Microneedles Loaded with IGF-1 for the Treatment of Androgenetic Alopecia

    Xing Zheng, Wenhao Yang, Chen Zhao, Yuhui Wang, Xiaolian Jiang, Qian Song, Yun Chu, Xia Jiang, Cheng Wang, Jianhao Wang
    New to Minoxidil? There is a guide in the encyclopedia. Read the guide →
    Studysummary In this study, an innovative microneedle platform loaded with IGF-1 and modified collagen was reported to significantly promote hair regeneration, enhance neovascularization, and reduce inflammation in a mouse model of androgenetic alopecia, outperforming the commonly used minoxidil treatment.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The study presents a novel treatment for androgenetic alopecia (AGA) using borate-modified recombinant type XVII collagen microneedles (I-mCOL17 MNs) loaded with IGF-1. These microneedles are designed to enhance the delivery and efficacy of growth factors by overcoming skin barriers and responding to changes in the microenvironment. In murine models, the I-mCOL17 MNs demonstrated superior performance compared to minoxidil, promoting hair regeneration, enhancing neovascularization, and reducing inflammation. This innovative approach offers a safer and more efficient strategy for AGA treatment, providing new hope for patients with this common form of hair loss.
    Discuss this study in the Community →

    Research cited in this study

    23 / 23 results